Notably, Subbiah et al. reported the first documented case of GNET harbouring an EWSR1-CREB1 fusion, in which the patient achieved a significant and durable clinical response to combination therapy with the receptor tyrosine kinase inhibitors crizotinib and pazopanib, maintaining clinical benefit for over 1.5 years [24]. Here, CREB1 is linked to gastric neuroendocrine tumor, well differentiated, low or intermediate grade.